The TOR Signaling Cascade Regulates Gene Expression in Response to Nutrients
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Aberrant Modulation of Ribosomal Protein S6 Phosphorylation Confers Acquired Resistance to MAPK Pathway Inhibitors in BRAF-Mutant Melanoma
www.nature.com/aps ARTICLE Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma Ming-zhao Gao1,2, Hong-bin Wang1,2, Xiang-ling Chen1,2, Wen-ting Cao1,LiFu1, Yun Li1, Hai-tian Quan1,2, Cheng-ying Xie1,2 and Li-guang Lou1,2 BRAF and MEK inhibitors have shown remarkable clinical efficacy in BRAF-mutant melanoma; however, most patients develop resistance, which limits the clinical benefit of these agents. In this study, we found that the human melanoma cell clones, A375-DR and A375-TR, with acquired resistance to BRAF inhibitor dabrafenib and MEK inhibitor trametinib, were cross resistant to other MAPK pathway inhibitors. In these resistant cells, phosphorylation of ribosomal protein S6 (rpS6) but not phosphorylation of ERK or p90 ribosomal S6 kinase (RSK) were unable to be inhibited by MAPK pathway inhibitors. Notably, knockdown of rpS6 in these cells effectively downregulated G1 phase-related proteins, including RB, cyclin D1, and CDK6, induced cell cycle arrest, and inhibited proliferation, suggesting that aberrant modulation of rpS6 phosphorylation contributed to the acquired resistance. Interestingly, RSK inhibitor had little effect on rpS6 phosphorylation and cell proliferation in resistant cells, whereas P70S6K inhibitor showed stronger inhibitory effects on rpS6 phosphorylation and cell proliferation in resistant cells than in parental cells. Thus regulation of rpS6 phosphorylation, which is predominantly mediated by BRAF/MEK/ERK/RSK signaling in parental cells, was switched to mTOR/ P70S6K signaling in resistant cells. Furthermore, mTOR inhibitors alone overcame acquired resistance and rescued the sensitivity of the resistant cells when combined with BRAF/MEK inhibitors. -
Allele-Specific Expression of Ribosomal Protein Genes in Interspecific Hybrid Catfish
Allele-specific Expression of Ribosomal Protein Genes in Interspecific Hybrid Catfish by Ailu Chen A dissertation submitted to the Graduate Faculty of Auburn University in partial fulfillment of the requirements for the Degree of Doctor of Philosophy Auburn, Alabama August 1, 2015 Keywords: catfish, interspecific hybrids, allele-specific expression, ribosomal protein Copyright 2015 by Ailu Chen Approved by Zhanjiang Liu, Chair, Professor, School of Fisheries, Aquaculture and Aquatic Sciences Nannan Liu, Professor, Entomology and Plant Pathology Eric Peatman, Associate Professor, School of Fisheries, Aquaculture and Aquatic Sciences Aaron M. Rashotte, Associate Professor, Biological Sciences Abstract Interspecific hybridization results in a vast reservoir of allelic variations, which may potentially contribute to phenotypical enhancement in the hybrids. Whether the allelic variations are related to the downstream phenotypic differences of interspecific hybrid is still an open question. The recently developed genome-wide allele-specific approaches that harness high- throughput sequencing technology allow direct quantification of allelic variations and gene expression patterns. In this work, I investigated allele-specific expression (ASE) pattern using RNA-Seq datasets generated from interspecific catfish hybrids. The objective of the study is to determine the ASE genes and pathways in which they are involved. Specifically, my study investigated ASE-SNPs, ASE-genes, parent-of-origins of ASE allele and how ASE would possibly contribute to heterosis. My data showed that ASE was operating in the interspecific catfish system. Of the 66,251 and 177,841 SNPs identified from the datasets of the liver and gill, 5,420 (8.2%) and 13,390 (7.5%) SNPs were identified as significant ASE-SNPs, respectively. -
Mtorc1 Controls Mitochondrial Activity and Biogenesis Through 4E-BP-Dependent Translational Regulation
Cell Metabolism Article mTORC1 Controls Mitochondrial Activity and Biogenesis through 4E-BP-Dependent Translational Regulation Masahiro Morita,1,2 Simon-Pierre Gravel,1,2 Vale´ rie Che´ nard,1,2 Kristina Sikstro¨ m,3 Liang Zheng,4 Tommy Alain,1,2 Valentina Gandin,5,7 Daina Avizonis,2 Meztli Arguello,1,2 Chadi Zakaria,1,2 Shannon McLaughlan,5,7 Yann Nouet,1,2 Arnim Pause,1,2 Michael Pollak,5,6,7 Eyal Gottlieb,4 Ola Larsson,3 Julie St-Pierre,1,2,* Ivan Topisirovic,5,7,* and Nahum Sonenberg1,2,* 1Department of Biochemistry 2Goodman Cancer Research Centre McGill University, Montreal, QC H3A 1A3, Canada 3Department of Oncology-Pathology, Karolinska Institutet, Stockholm, 171 76, Sweden 4Cancer Research UK, The Beatson Institute for Cancer Research, Switchback Road, Glasgow G61 1BD, Scotland, UK 5Lady Davis Institute for Medical Research 6Cancer Prevention Center, Sir Mortimer B. Davis-Jewish General Hospital McGill University, Montreal, QC H3T 1E2, Canada 7Department of Oncology, McGill University, Montreal, QC H2W 1S6, Canada *Correspondence: [email protected] (J.S.-P.), [email protected] (I.T.), [email protected] (N.S.) http://dx.doi.org/10.1016/j.cmet.2013.10.001 SUMMARY ATP under physiological conditions in mammals and play a crit- ical role in overall energy balance (Vander Heiden et al., 2009). mRNA translation is thought to be the most energy- The mechanistic/mammalian target of rapamycin (mTOR) is a consuming process in the cell. Translation and serine/threonine kinase that has been implicated in a variety of energy metabolism are dysregulated in a variety of physiological processes and pathological states (Zoncu et al., diseases including cancer, diabetes, and heart 2011). -
Differential Requirement of the Ribosomal Protein S6 And
Plant Pathology and Microbiology Publications Plant Pathology and Microbiology 5-2017 Differential Requirement of the Ribosomal Protein S6 and Ribosomal Protein S6 Kinase for Plant- Virus Accumulation and Interaction of S6 Kinase with Potyviral VPg Minna-Liisa Rajamäki University of Helsinki Dehui Xi Sichuan University Sidona Sikorskaite-Gudziuniene University of Helsinki Jari P. T. Valkonen University of Helsinki Follow this and additional works at: http://lib.dr.iastate.edu/plantpath_pubs StevePanr tA of. W thehithAgramicultural Science Commons, Agriculture Commons, Plant Breeding and Genetics CIowommona State Usn, iaverndsit they, swPhithlanatm@i Pathoastalote.geduy Commons The ompc lete bibliographic information for this item can be found at http://lib.dr.iastate.edu/ plantpath_pubs/211. For information on how to cite this item, please visit http://lib.dr.iastate.edu/ howtocite.html. This Article is brought to you for free and open access by the Plant Pathology and Microbiology at Iowa State University Digital Repository. It has been accepted for inclusion in Plant Pathology and Microbiology Publications by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Differential Requirement of the Ribosomal Protein S6 and Ribosomal Protein S6 Kinase for Plant-Virus Accumulation and Interaction of S6 Kinase with Potyviral VPg Abstract Ribosomal protein S6 (RPS6) is an indispensable plant protein regulated, in part, by ribosomal protein S6 kinase (S6K) which, in turn, is a key regulator of plant responses to stresses and developmental cues. Increased expression of RPS6 was detected in Nicotiana benthamiana during infection by diverse plant viruses. Silencing of the RPS6and S6K genes in N. -
Transcriptional Changes Induced by Epigenetic Therapy with Hydralazine and Magnesium Valproate in Cervical Carcinoma
399-407.qxd 20/12/2010 11:45 Ì ™ÂÏ›‰·399 ONCOLOGY REPORTS 25: 399-407, 2011 399 Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma ERICK DE LA CRUZ-HERNÁNDEZ1, CARLOS PEREZ-PLASENCIA1, ENRIQUE PÉREZ-CARDENAS1, AURORA GONZALEZ-FIERRO1, CATALINA TREJO-BECERRIL1, ALMA CHÁVEZ-BLANCO1, LUCIA TAJA-CHAYEB1, SILVIA VIDAL1, OLGA GUTIÉRREZ1, GUADALUPE I. DOMINGUEZ1, JAENAI E. TRUJILLO1 and ALFONSO DUENAS-GONZÁLEZ2 1Unidad de Investigación Biomédica en Cáncer, Instituto de Investigaciones Biomédicas (IIB), Universidad Nacional Autonóma de Mexico (UNAM), Instituto Nacional de Cancerología (INCan), Mexico City; 2Division of Basic Research, Instituto Nacional de Cancerologia, Mexico City, Mexico Received July 1, 2010; Accepted September 29, 2010 DOI: 10.3892/or.2010.1086 Abstract. Aberrant DNA methylation and histone deacety- Introduction lation participate in cancer development and progression; hence, their reversal by inhibitors of DNA methylation and DNA methylation (DNMT) and histone deacetylase inhi- histone deacetylases is a promising cancer therapy. Experi- bitors (HDAC) exert their antitumor effects by inhibiting mental data demonstrate that these inhibitors in combination cell proliferation, metastases, angiogenesis, and by inducing do not only show synergy in antitumor effects but also in cell differentiation and/or apoptosis, as well as by increasing whole genome global expression. Ten pairs of pre- and post- chemotherapy cytotoxicity (1-5). Further, these epigenetic treatment cervical tumor samples were analyzed by micro- drugs are radiosensitizers (6-8). array analysis. Treatment for seven days with hydralazine The rationale for utilizing these epigenetic drugs for and valproate (HV) in patients up-regulated 964 genes. The cancer treatment has relied on the theory that reversing epi- two pathways possessing the highest number of up-regulated genetic aberrations would turn-on tumor suppressor genes genes comprised the ribosome protein and the oxidative and consequently exert antitumor effects. -
Supplementary Table 2
Supplementary Table 2. Differentially Expressed Genes following Sham treatment relative to Untreated Controls Fold Change Accession Name Symbol 3 h 12 h NM_013121 CD28 antigen Cd28 12.82 BG665360 FMS-like tyrosine kinase 1 Flt1 9.63 NM_012701 Adrenergic receptor, beta 1 Adrb1 8.24 0.46 U20796 Nuclear receptor subfamily 1, group D, member 2 Nr1d2 7.22 NM_017116 Calpain 2 Capn2 6.41 BE097282 Guanine nucleotide binding protein, alpha 12 Gna12 6.21 NM_053328 Basic helix-loop-helix domain containing, class B2 Bhlhb2 5.79 NM_053831 Guanylate cyclase 2f Gucy2f 5.71 AW251703 Tumor necrosis factor receptor superfamily, member 12a Tnfrsf12a 5.57 NM_021691 Twist homolog 2 (Drosophila) Twist2 5.42 NM_133550 Fc receptor, IgE, low affinity II, alpha polypeptide Fcer2a 4.93 NM_031120 Signal sequence receptor, gamma Ssr3 4.84 NM_053544 Secreted frizzled-related protein 4 Sfrp4 4.73 NM_053910 Pleckstrin homology, Sec7 and coiled/coil domains 1 Pscd1 4.69 BE113233 Suppressor of cytokine signaling 2 Socs2 4.68 NM_053949 Potassium voltage-gated channel, subfamily H (eag- Kcnh2 4.60 related), member 2 NM_017305 Glutamate cysteine ligase, modifier subunit Gclm 4.59 NM_017309 Protein phospatase 3, regulatory subunit B, alpha Ppp3r1 4.54 isoform,type 1 NM_012765 5-hydroxytryptamine (serotonin) receptor 2C Htr2c 4.46 NM_017218 V-erb-b2 erythroblastic leukemia viral oncogene homolog Erbb3 4.42 3 (avian) AW918369 Zinc finger protein 191 Zfp191 4.38 NM_031034 Guanine nucleotide binding protein, alpha 12 Gna12 4.38 NM_017020 Interleukin 6 receptor Il6r 4.37 AJ002942 -
Inhibition of the MID1 Protein Complex
Matthes et al. Cell Death Discovery (2018) 4:4 DOI 10.1038/s41420-017-0003-8 Cell Death Discovery ARTICLE Open Access Inhibition of the MID1 protein complex: a novel approach targeting APP protein synthesis Frank Matthes1,MoritzM.Hettich1, Judith Schilling1, Diana Flores-Dominguez1, Nelli Blank1, Thomas Wiglenda2, Alexander Buntru2,HannaWolf1, Stephanie Weber1,InaVorberg 1, Alina Dagane2, Gunnar Dittmar2,3,ErichWanker2, Dan Ehninger1 and Sybille Krauss1 Abstract Alzheimer’s disease (AD) is characterized by two neuropathological hallmarks: senile plaques, which are composed of amyloid-β (Aβ) peptides, and neurofibrillary tangles, which are composed of hyperphosphorylated tau protein. Aβ peptides are derived from sequential proteolytic cleavage of the amyloid precursor protein (APP). In this study, we identified a so far unknown mode of regulation of APP protein synthesis involving the MID1 protein complex: MID1 binds to and regulates the translation of APP mRNA. The underlying mode of action of MID1 involves the mTOR pathway. Thus, inhibition of the MID1 complex reduces the APP protein level in cultures of primary neurons. Based on this, we used one compound that we discovered previously to interfere with the MID1 complex, metformin, for in vivo experiments. Indeed, long-term treatment with metformin decreased APP protein expression levels and consequently Aβ in an AD mouse model. Importantly, we have initiated the metformin treatment late in life, at a time-point where mice were in an already progressed state of the disease, and could observe an improved behavioral phenotype. These 1234567890 1234567890 findings together with our previous observation, showing that inhibition of the MID1 complex by metformin also decreases tau phosphorylation, make the MID1 complex a particularly interesting drug target for treating AD. -
The Ribosomal Protein Genes and Minute Loci of Drosophila
Open Access Research2007MarygoldetVolume al. 8, Issue 10, Article R216 The ribosomal protein genes and Minute loci of Drosophila melanogaster Steven J Marygold*, John Roote†, Gunter Reuter‡, Andrew Lambertsson§, Michael Ashburner†, Gillian H Millburn†, Paul M Harrison¶, Zhan Yu¶, Naoya Kenmochi¥, Thomas C Kaufman#, Sally J Leevers* and Kevin R Cook# Addresses: *Growth Regulation Laboratory, Cancer Research UK London Research Institute, Lincoln's Inn Fields, London WC2A 3PX, UK. †Department of Genetics, University of Cambridge, Downing Street, Cambridge CB2 3EH, UK. ‡Institute of Genetics, Biologicum, Martin Luther University Halle-Wittenberg, Weinbergweg, Halle D-06108, Germany. §Institute of Molecular Biosciences, University of Oslo, Blindern, Olso N-0316, Norway. ¶Department of Biology, McGill University, Dr Penfield Ave, Montreal, Quebec H3A 1B1, Canada. ¥Frontier Science Research Center, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan. #Department of Biology, Indiana University, E. Third Street, Bloomington, IN 47405-7005, USA. Correspondence: Steven J Marygold. Email: [email protected]. Kevin R Cook. Email: [email protected] Published: 10 October 2007 Received: 17 June 2007 Revised: 10 October 2007 Genome Biology 2007, 8:R216 (doi:10.1186/gb-2007-8-10-r216) Accepted: 10 October 2007 The electronic version of this article is the complete one and can be found online at http://genomebiology.com/2007/8/10/R216 © 2007 Marygold et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. -
C6orf203 Controls OXPHOS Function Through Modulation of Mitochondrial Protein Biosynthesis
bioRxiv preprint doi: https://doi.org/10.1101/704403; this version posted July 17, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. C6orf203 controls OXPHOS function through modulation of mitochondrial protein biosynthesis number of characters excluding Materials and Methods: 40,651 Sara Palacios-Zambrano1,2, Luis Vázquez-Fonseca1,2, Cristina González-Páramos1,2, Laura Mamblona1,2, Laura Sánchez-Caballero3, Leo Nijtmans3, Rafael Garesse1,2 and Miguel Angel Fernández-Moreno1,2,* 1 Departamento de Bioquímica, Instituto de Investigaciones Biomédicas “Alberto Sols” UAM CSIC and Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER). Facultad de Medicina, Universidad Autónoma de Madrid. Madrid 28029, Spain. 2 Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid 28041, Spain. 3 Department of Pediatrics, Radboud Center for Mitochondrial Medicine, Radboud University Medical Center, Nijmegen, The Netherlands. * To whom correspondence should be addressed. Tel:+34 91 497 31 29; Email: [email protected] Running title “C6orf203 controls mt-proteins synthesis” bioRxiv preprint doi: https://doi.org/10.1101/704403; this version posted July 17, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. ABSTRACT Mitochondria are essential organelles present in the vast majority of eukaryotic cells. Their central function is to produce cellular energy through the OXPHOS system, and functional alterations provoke so-called mitochondrial OXPHOS diseases. It is estimated that several hundred mitochondrial proteins have unknown functions. Very recently, C6orf203 was described to participate in mitochondrial transcription under induced mitochondrial DNA depletion stress conditions. -
Ferret MRPL39 ORF Mammalian Expression Plasmid, N-Flag Tag
Ferret MRPL39 ORF mammalian expression plasmid, N-Flag tag Catalog Number: FG60159-NF General Information Plasmid Resuspension protocol Gene : mitochondrial ribosomal protein L39 1. Centrifuge at 5,000×g for 5 min. Official Symbol : MRPL39 2. Carefully open the tube and add 100 l of sterile water to Synonym : MRPL39 dissolve the DNA. Source : Ferret 3. Close the tube and incubate for 10 minutes at room cDNA Size: 1008bp temperature. RefSeq : XM_004757437.1 4. Briefly vortex the tube and then do a quick spin to Description concentrate the liquid at the bottom. Speed is less than Lot : Please refer to the label on the tube 5000×g. Vector : pCMV3-N-FLAG 5. Store the plasmid at -20 ℃. Shipping carrier : Each tube contains approximately 10 μg of lyophilized plasmid. The plasmid is ready for: Storage : • Restriction enzyme digestion The lyophilized plasmid can be stored at ambient temperature for three months. • PCR amplification Quality control : • E. coli transformation The plasmid is confirmed by full-length sequencing with primers • DNA sequencing in the sequencing primer list. Sequencing primer list : E.coli strains for transformation (recommended but not limited) pCMV3-F: 5’ CAGGTGTCCACTCCCAGGTCCAAG 3’ Most commercially available competent cells are appropriate for pcDNA3-R : 5’ GGCAACTAGAAGGCACAGTCGAGG 3’ the plasmid, e.g. TOP10, DH5α and TOP10F´. Or Forward T7 : 5’ TAATACGACTCACTATAGGG 3’ ReverseBGH : 5’ TAGAAGGCACAGTCGAGG 3’ pCMV3-F and pcDNA3-R are designed by Sino Biological Inc. Customers can order the primer pair from any oligonucleotide supplier. Manufactured By Sino Biological Inc., FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS. Fax :+86-10-51029969 Tel:+86- 400-890-9989 http://www.sinobiological.com Ferret MRPL39 ORF mammalian expression plasmid, N-Flag tag Catalog Number: FG60159-NF Vector Information All of the pCMV vectors are designed for high-level stable and transient expression in mammalian hosts. -
Transcriptomic and Proteomic Landscape of Mitochondrial
TOOLS AND RESOURCES Transcriptomic and proteomic landscape of mitochondrial dysfunction reveals secondary coenzyme Q deficiency in mammals Inge Ku¨ hl1,2†*, Maria Miranda1†, Ilian Atanassov3, Irina Kuznetsova4,5, Yvonne Hinze3, Arnaud Mourier6, Aleksandra Filipovska4,5, Nils-Go¨ ran Larsson1,7* 1Department of Mitochondrial Biology, Max Planck Institute for Biology of Ageing, Cologne, Germany; 2Department of Cell Biology, Institute of Integrative Biology of the Cell (I2BC) UMR9198, CEA, CNRS, Univ. Paris-Sud, Universite´ Paris-Saclay, Gif- sur-Yvette, France; 3Proteomics Core Facility, Max Planck Institute for Biology of Ageing, Cologne, Germany; 4Harry Perkins Institute of Medical Research, The University of Western Australia, Nedlands, Australia; 5School of Molecular Sciences, The University of Western Australia, Crawley, Australia; 6The Centre National de la Recherche Scientifique, Institut de Biochimie et Ge´ne´tique Cellulaires, Universite´ de Bordeaux, Bordeaux, France; 7Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden Abstract Dysfunction of the oxidative phosphorylation (OXPHOS) system is a major cause of human disease and the cellular consequences are highly complex. Here, we present comparative *For correspondence: analyses of mitochondrial proteomes, cellular transcriptomes and targeted metabolomics of five [email protected] knockout mouse strains deficient in essential factors required for mitochondrial DNA gene (IKu¨ ); expression, leading to OXPHOS dysfunction. Moreover, -
Using the Ts65dn Mouse Model of Down Syndrome to Understand the Genetics of Congenital Heart Defects
USING THE TS65DN MOUSE MODEL OF DOWN SYNDROME TO UNDERSTAND THE GENETICS OF CONGENITAL HEART DEFECTS by Renita Polk A dissertation submitted to Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland March, 2014 © 2014 Renita Polk All Rights Reserved Abstract Down syndrome (DS) is the most common chromosomal abnormality in humans, caused by having three copies of human chromosome 21 (Hsa21). It is associated with a variety of features affecting almost every organ system, including the heart. There is an especially high incidence of congenital heart defect (CHD) in DS, where 40 – 50% of affected individuals have a CHD. CHD is the most common congenital defect in live births. The fact that half of those with DS have a normal heart suggests that additional genetic and environmental factors interact with trisomy 21 to cause CHD. Thus, people with trisomy 21 are sensitized to CHD. The Ts65Dn mouse model of DS was used as an analogous sensitized population to study the role of the Tbx5 gene in CHD. Tbx5 is a modifier of CHD known to play a role in chamber formation and septation of the heart. A Tbx5 null allele was introduced to Ts65Dn mice, and newborn pups were sacrificed and examined for CHDs. There is a significant difference between trisomic and euploid pups in the frequency of overriding aorta (OA). About 58% of the trisomic Tbx5+/- mice present with OA and a ventricular septal defect (VSD), while only 18% of the euploid pups have this defect. These results suggest that there is an interaction between Tbx5 and trisomy to increase the frequency of specific defects, and suggests a role for Tbx5 in development of the aorta.